{"database": "lobbying", "table": "lobbying_activities", "rows": [[2677742, "8858a006-cb0f-4089-a008-ae3d743d72ce", "Q3", "RED+BLUE STRATEGIES", 400693064, "COHERUS BIOSCIENCES", 2021, "third_quarter", "PHA", "Build Back Better Act - Issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications\n\nWork to advance policies that support companies that fully manufacture products in America. \n\n\nS. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. \n\nIssues and policies that incent companies to increase their US footprint and adopt Made in America business practices. \n\nPolicies to help grow the biosimilars marketplace in the United States. \n\nPolicies focused on improving cancer care through access to affordable treatments.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-11T09:33:13.227000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2677742"], "units": {}, "query_ms": 0.3759460523724556, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}